Clinical trials
Locally Recurrent Rectal Cancer clinical trials
Below are recruiting locally recurrent rectal cancer clinical trials, each written for real people, not researchers. We’re tracking 60 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06209099Recruiting
Organ preservation first for low-risk rectal cancer
This trial tests a strategy to avoid surgery by using watchful waiting after initial treatment for early-stage rectal cancer. It may help patients keep their rectum and avoid a permanent colostomy.
Beijing, Haidian DistrictAges 18–85 - NCT06936774RecruitingPhase 3
Intensive follow-up after rectal cancer surgery to improve recovery
This study tests whether a more intensive follow-up program after rectal cancer surgery can improve your recovery, daily function, and overall quality of life. If you've had a temporary ileostomy and are waiting for reversal, this extra support may help you feel better faster.
BaselAges 18 years+ - NCT06940388RecruitingPhase 2
Immunotherapy plus standard treatment for rectal cancer
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
MainzAges 18 years+ - NCT06787183RecruitingPhase 2
Short-course radiation with chemoimmunotherapy for rectal cancer that has spread to the liver
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Fuzhou, FujianAges 18–75 - NCT06767007RecruitingPhase 2
Radiation plus immunotherapy for recurrent rectal cancer
This trial studies a combination of SBRT (a precise kind of radiation) and an immunotherapy drug (PD-1 antibody) for people whose rectal cancer has come back in the pelvis and cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or stop it from growing.
Guangzhou, GuangdongAges 18–75 - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT05576480RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for rectal cancer without mismatch repair
This Phase 2 study tests penpulimab (an immunotherapy medicine) given with CAPEOX chemotherapy before surgery for rectal cancer that is “MSS” (not the mismatch-repair type). It aims to shrink the tumor and improve outcomes by treating before the operation.
Shanghai, None SelectedAges 18–75 - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06052332Recruiting
Comparing two pre-surgery treatments for older adults with rectal cancer
This study compares two approaches to treating rectal cancer in people age 70 and older who have not yet had surgery. One approach gives chemotherapy and radiation before surgery, and the other adds more chemotherapy after radiation. The goal is to find which plan works better with fewer side effects.
Antwerp, AntwerpenAges 70 years+ - NCT05731726RecruitingPhase 2
New treatment before surgery for locally advanced rectal cancer
This trial tests whether giving serplulimab (an immune medicine) plus CAPEOX chemotherapy and celecoxib before surgery can shrink locally advanced rectal cancer and improve outcomes. It may help by increasing immune attack on the tumor while chemotherapy helps reduce the cancer before the operation.
Hangzhou, ZhejiangAges 18–75 - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT03516708RecruitingPhase 1/Phase 2
Epacadostat with pre-op radiation for locally advanced rectal cancer
This trial studies whether adding epacadostat (a cancer drug) to standard pre-operative chemoradiation can improve outcomes for people with locally advanced rectal cancer. It’s designed to see if the added treatment is safe and potentially more effective before surgery.
Orange, CaliforniaAges 18 years+ - NCT06770270RecruitingPhase 2
Immunotherapy with radiation and chemo before rectal cancer surgery
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT04525989Recruiting
Short-course proton vs photon radiation before rectal surgery
This study compares two types of pre-surgery radiation—protons versus standard photons—in people with high-risk rectal cancer. The goal is to shrink and control the tumor while safely getting you ready for surgery, and to see which approach works better.
Stockholm, SolnaAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT05984576Recruiting
Chemo and radiation for recurrent rectal cancer after prior pelvic radiation
This study looks at combining total neoadjuvant therapy (chemotherapy and radiation) for rectal cancer that has come back in the pelvis after earlier radiation. It aims to see if this treatment approach can help control the disease and improve outcomes in patients with limited spread that can potentially be removed or treated.
RomeAges 18 years+ - NCT06846268RecruitingPhase 2
New drug combo before surgery for colorectal cancer
This trial tests two immunotherapy drugs (ADG126 and pembrolizumab) given before surgery for locally advanced colorectal cancer that hasn't spread. It aims to shrink tumors and improve outcomes.
SingaporeAges 21 years+ - NCT06843434RecruitingPhase 2
Study of two immunotherapy drugs for rectal cancer
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
La Jolla, CaliforniaAges 18 years+ - NCT05563922RecruitingPhase 2
Testing a plan to preserve the anus after rectal chemo-radiation
This Phase 2 study tests a “total neoadjuvant” (chemo plus radiation before the main treatment) plan to see if some people with low rectal cancer can keep their anus. It may help you avoid permanent colostomy if your cancer responds well and you meet the study rules.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04927897Recruiting
Testing where to aim extra rectal radiation before surgery
This trial tests the best place to target an “extra boost” of radiation inside the rectum for certain rectal cancer patients. It may help guide more precise treatment planning before they have total mesorectal excision (TME) surgery.
Maastricht, LimburgAges 18 years+ - NCT06926374Recruiting
Robotic surgery for gastrointestinal and urologic conditions
This trial tests a new robotic surgery system for common operations on the colon, rectum, prostate, kidney, bladder, stomach, esophagus, gallbladder, and hiatal hernia. It may offer a less invasive option for patients who need surgery for these conditions.
Hong KongAges 18–80 - NCT07425054RecruitingPhase 2
Chemoradiation with or without immunotherapy for anal cancer
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
Cleveland, OhioAges 18 years+ - NCT05186116Recruiting
Liver transplant for colon cancer that cannot be removed
This trial studies whether liver transplant (rather than removing the liver tumors) can help some people with colon or rectal cancer spread to the liver. It’s meant for people whose cancer has responded or stayed controlled on standard treatments and who have no cancer outside the liver.
Modena, MOAges 18–77
Hear when a new Locally Recurrent Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally recurrent rectal cancer?
- Yes. Clin2 currently lists 60 recruiting locally recurrent rectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally recurrent rectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally recurrent rectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.